Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:34 ET | 18915 | 2.64 |
09:36 ET | 400 | 2.625 |
09:38 ET | 13359 | 2.605 |
09:39 ET | 100 | 2.605 |
09:41 ET | 6233 | 2.61 |
09:43 ET | 1368 | 2.61 |
09:45 ET | 1583 | 2.61 |
09:48 ET | 250 | 2.607 |
09:50 ET | 2282 | 2.59 |
09:54 ET | 15834 | 2.59 |
09:56 ET | 600 | 2.595 |
09:57 ET | 100 | 2.59 |
09:59 ET | 1940 | 2.61 |
10:01 ET | 16269 | 2.605 |
10:03 ET | 4499 | 2.59 |
10:06 ET | 2819 | 2.6 |
10:08 ET | 6721 | 2.58 |
10:10 ET | 12060 | 2.58 |
10:12 ET | 7305 | 2.585 |
10:14 ET | 5245 | 2.59 |
10:15 ET | 3634 | 2.5866 |
10:17 ET | 2065 | 2.6 |
10:19 ET | 400 | 2.595 |
10:21 ET | 531 | 2.59 |
10:24 ET | 5082 | 2.605 |
10:26 ET | 8502 | 2.605 |
10:28 ET | 171959 | 2.615 |
10:30 ET | 2800 | 2.61 |
10:32 ET | 7967 | 2.63 |
10:33 ET | 17635 | 2.6475 |
10:35 ET | 14747 | 2.625 |
10:37 ET | 10985 | 2.63 |
10:39 ET | 2331 | 2.63 |
10:42 ET | 4639 | 2.66 |
10:44 ET | 869 | 2.65 |
10:46 ET | 54361 | 2.695 |
10:48 ET | 19250 | 2.725 |
10:50 ET | 9068 | 2.69 |
10:51 ET | 4032 | 2.68 |
10:53 ET | 45140 | 2.72 |
10:55 ET | 135924 | 2.695 |
10:57 ET | 7496 | 2.705 |
11:00 ET | 22064 | 2.725 |
11:02 ET | 4408 | 2.73 |
11:04 ET | 6314 | 2.71 |
11:06 ET | 5434 | 2.71 |
11:08 ET | 18698 | 2.72 |
11:09 ET | 5714 | 2.73 |
11:11 ET | 4155 | 2.73 |
11:13 ET | 21256 | 2.73 |
11:15 ET | 1100 | 2.73 |
11:18 ET | 5895 | 2.73 |
11:20 ET | 400 | 2.73 |
11:22 ET | 7464 | 2.725 |
11:24 ET | 3427 | 2.73 |
11:26 ET | 3327 | 2.73 |
11:27 ET | 7670 | 2.715 |
11:29 ET | 1200 | 2.7124 |
11:31 ET | 6832 | 2.715 |
11:33 ET | 901 | 2.72 |
11:36 ET | 300 | 2.725 |
11:38 ET | 2617 | 2.725 |
11:40 ET | 400 | 2.725 |
11:42 ET | 5775 | 2.715 |
11:44 ET | 4153 | 2.72 |
11:45 ET | 200 | 2.72 |
11:47 ET | 300 | 2.725 |
11:49 ET | 600 | 2.725 |
11:51 ET | 6117 | 2.7308 |
11:54 ET | 3006 | 2.735 |
11:56 ET | 4559 | 2.735 |
11:58 ET | 1260 | 2.735 |
12:00 ET | 6153 | 2.72 |
12:02 ET | 300 | 2.72 |
12:03 ET | 595 | 2.725 |
12:05 ET | 200 | 2.722 |
12:07 ET | 261935 | 2.73 |
12:09 ET | 53709 | 2.755 |
12:12 ET | 48688 | 2.735 |
12:16 ET | 200 | 2.735 |
12:18 ET | 1552 | 2.73 |
12:20 ET | 100 | 2.735 |
12:21 ET | 4266 | 2.725 |
12:23 ET | 222572 | 2.72 |
12:25 ET | 15249 | 2.745 |
12:27 ET | 100 | 2.74 |
12:30 ET | 400 | 2.74 |
12:32 ET | 1378 | 2.75 |
12:34 ET | 11193 | 2.77 |
12:36 ET | 630 | 2.7791 |
12:38 ET | 2100 | 2.785 |
12:39 ET | 100 | 2.79 |
12:41 ET | 100 | 2.79 |
12:43 ET | 37053 | 2.77 |
12:45 ET | 600 | 2.77 |
12:48 ET | 946 | 2.77 |
12:50 ET | 848 | 2.77 |
12:52 ET | 282 | 2.77 |
12:54 ET | 359 | 2.77 |
12:56 ET | 248 | 2.775 |
12:57 ET | 712 | 2.775 |
12:59 ET | 3761 | 2.77 |
01:01 ET | 2429 | 2.775 |
01:03 ET | 300 | 2.775 |
01:06 ET | 100 | 2.775 |
01:08 ET | 463 | 2.7701 |
01:10 ET | 4530 | 2.79 |
01:12 ET | 2000 | 2.795 |
01:14 ET | 400 | 2.8 |
01:15 ET | 1303 | 2.805 |
01:17 ET | 700 | 2.81 |
01:19 ET | 500 | 2.81 |
01:21 ET | 7925 | 2.7902 |
01:24 ET | 835 | 2.795 |
01:26 ET | 2651 | 2.805 |
01:28 ET | 6124 | 2.79 |
01:30 ET | 549 | 2.785 |
01:32 ET | 43370 | 2.75 |
01:33 ET | 8402 | 2.75 |
01:35 ET | 800 | 2.76 |
01:37 ET | 700 | 2.76 |
01:39 ET | 8126 | 2.76 |
01:42 ET | 4829 | 2.76 |
01:44 ET | 1262 | 2.755 |
01:46 ET | 11400 | 2.755 |
01:48 ET | 700 | 2.76 |
01:50 ET | 8656 | 2.745 |
01:51 ET | 577 | 2.75 |
01:53 ET | 3855 | 2.76 |
01:55 ET | 3660 | 2.765 |
01:57 ET | 599 | 2.77 |
02:00 ET | 900 | 2.76 |
02:02 ET | 5865 | 2.75 |
02:04 ET | 913 | 2.75 |
02:06 ET | 919 | 2.755 |
02:08 ET | 1608 | 2.755 |
02:09 ET | 4925 | 2.74 |
02:11 ET | 1100 | 2.745 |
02:13 ET | 500 | 2.75 |
02:15 ET | 300 | 2.745 |
02:18 ET | 511 | 2.745 |
02:20 ET | 200 | 2.75 |
02:22 ET | 507 | 2.745 |
02:24 ET | 300 | 2.745 |
02:26 ET | 1400 | 2.745 |
02:27 ET | 8781 | 2.73 |
02:29 ET | 500 | 2.74 |
02:31 ET | 601 | 2.735 |
02:33 ET | 500 | 2.74 |
02:36 ET | 800 | 2.735 |
02:38 ET | 963 | 2.735 |
02:40 ET | 900 | 2.735 |
02:42 ET | 600 | 2.735 |
02:44 ET | 1994 | 2.735 |
02:45 ET | 800 | 2.74 |
02:47 ET | 1295 | 2.735 |
02:49 ET | 2107 | 2.74 |
02:51 ET | 1400 | 2.74 |
02:54 ET | 7525 | 2.75 |
02:56 ET | 28132 | 2.77 |
02:58 ET | 7731 | 2.765 |
03:00 ET | 12164 | 2.775 |
03:02 ET | 2244 | 2.78 |
03:03 ET | 1049 | 2.78 |
03:05 ET | 14792 | 2.8 |
03:07 ET | 1381 | 2.8 |
03:09 ET | 3275 | 2.8 |
03:12 ET | 1218 | 2.8 |
03:14 ET | 600 | 2.8 |
03:16 ET | 1471 | 2.795 |
03:18 ET | 781 | 2.795 |
03:20 ET | 1906 | 2.791 |
03:21 ET | 689 | 2.8 |
03:23 ET | 1745 | 2.8 |
03:25 ET | 2989 | 2.795 |
03:27 ET | 1800 | 2.8 |
03:30 ET | 15352 | 2.78 |
03:32 ET | 5175 | 2.8 |
03:34 ET | 7068 | 2.795 |
03:36 ET | 3496 | 2.8 |
03:38 ET | 1223 | 2.795 |
03:39 ET | 5278 | 2.81 |
03:41 ET | 5954 | 2.815 |
03:43 ET | 25144 | 2.795 |
03:45 ET | 5994 | 2.785 |
03:48 ET | 853 | 2.785 |
03:50 ET | 7140 | 2.795 |
03:52 ET | 3987 | 2.795 |
03:54 ET | 4587 | 2.8 |
03:56 ET | 7511 | 2.8 |
03:57 ET | 11508 | 2.795 |
03:59 ET | 60807 | 2.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 766.2M | -8.9x | --- |
Cogent Biosciences Inc | 765.9M | -3.6x | --- |
Viridian Therapeutics Inc | 762.7M | -2.7x | --- |
89Bio Inc | 777.2M | -4.0x | --- |
Prime Medicine Inc | 777.8M | -3.0x | --- |
Scholar Rock Holding Corp | 748.9M | -4.7x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $766.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 247.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.42 |
EPS | $-0.31 |
Book Value | $2.76 |
P/E Ratio | -8.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.